drugset / Trial / NCT02936635
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
Timeline
- Start
- 2016-10-17
- Primary completion
- 2018-10-26
- Completion
- 2018-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tirasemtiv | Other / unclassified | 250 mg | Oral |